The Chicago Sun-Times profiles Cytos' work on a new blood pressure vaccine. Just like new development work being done on vaccines for cancer, asthma and psoriasis, the trick is to identify a protein that plays a role in the disease and make it look like a virus. Early human data has backed Cytos' work in the area, demonstrating that its vaccine is safe and generated a potent immune response. Over a 12-week period, treatment provided in a 72-patient study reduced systolic pressure by 5.6 millimeters and diastolic pressure dropped 5.6 millimeters.
There are skeptics, though. Some say that any immune response to a vaccine could be short-lived, requiring regular boosters. Others wonder about the potential unexpected dangers involved in blocking a protein.
- read the article in the Chicago Sun-Times
Related Articles:
Cytos vaccine offers radically new approach. Report
Novartis, Cytos inks $500M anti-smoking vaccine pact. Report